

- The availability of data and/or, any information on product utilization, cost, the incidence, prevalence, and/or severity of the particular disease, health condition, adverse event or medical error relevant to the topic being nominated.

- Include, if relevant, the significance to Federal Health Programs or underserved populations; or an indication of how the research results or Center activities might be used within the professional or organizational setting.

AHCPR will not reply to individual responses, but will consider all responses in developing the CERTS program and selecting topics for study. AHCPR will review the submissions and supporting information before making final determinations, seeking additional information as appropriate.

Dated: October 26, 1998.

**John M. Eisenberg,**

*Administrator.*

[FR Doc. 98-29335 Filed 11-2-98; 8:45 am]

BILLING CODE 4160-90-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Advisory Committee for Energy-Related Epidemiologic Research and Subcommittee for Community Affairs: Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meetings.

*Name:* Advisory Committee for Energy-Related Epidemiologic Research (ACERER).

*Times and Dates:* 8:30 a.m.-5:15 p.m., November 19, 1998; 8:30 a.m.-12 noon, November 20, 1998.

*Place:* Radisson Plaza Hotel at Mark Center, 5000 Seminary Road, Alexandria, Virginia 22311, telephone 703/845-1010, fax 703/845-2610.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

*Purpose:* This committee is charged with providing advice and recommendations to the Secretary, HHS; the Assistant Secretary for Health; the Director, CDC; and the Administrator, Agency for Toxic Substances and Disease Registry (ATSDR), on establishment of a research agenda and the conduct of a research program pertaining to energy-related analytic epidemiologic studies.

*Matters to be Discussed:* Agenda items will include update presentations from the National Institute for Occupational Safety

and Health (NIOSH) and ATSDR on the progress of current studies; an update by the National Center for Environmental Health (NCEH) on coordination of activities with the National Cancer Institute (NCI); a presentation by NCI on Chernobyl, Radio Epi Tables and Ethel Gilbert's Research; a discussion by a panel of risk communications professionals on recommendations made by the National Academy of Sciences/Institutes of Medicine on the NCI report; and a discussion of committee recommendations and public involvement activities.

Agenda items are subject to change as priorities dictate.

*Name:* ACERER Subcommittee for Community Affairs.

*Times and Dates:* 1 p.m.-5 p.m., November 20, 1998; 8:30 a.m.-5 p.m., November 21, 1998.

*Place:* Radisson Plaza Hotel at Mark Center, 5000 Seminary Road, Alexandria, Virginia 22311, telephone 703/845-1010, fax 703/845-2610.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

*Purpose:* This subcommittee will advise ACERER on matters related to community needs and will report back to the Agency through the full committee.

*Matters to be Discussed:* Agenda items will include update presentations from NCEH, NIOSH, and ATSDR on the progress of current studies; a discussion of the September 24, 1998, ACERER meeting and the resolution resulting from that meeting; a discussion of a special report presented by the Tennessean newspaper on health problems in the vicinity of nuclear facilities; and a discussion of committee recommendations and public involvement activities.

Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* Michael J. Sage, Deputy Chief, Radiation Studies Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC, 4770 Buford Highway, NE., m/s F-35, Atlanta, Georgia 30341-3724, telephone 770/488-7040, fax 770/488-7044.

Dated: October 28, 1998.

**Carolyn J. Russell,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 98-29380 Filed 11-2-98; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 98N-0515]

#### Agency Information Collection Activities; Announcement of OMB Approval; Amendments to Humanitarian Use Device (HUD) Requirements

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Amendments to Humanitarian Use Device (HUD) Requirements" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).

**FOR FURTHER INFORMATION CONTACT:** Margaret R. Schlosburg, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223.

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of August 7, 1998 (63 FR 42404), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under section 3507 of the PRA (44 U.S.C. 3507). An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0384. The approval expires on October 31, 2001.

Dated: October 28, 1998.

**William K. Hubbard,**

*Associate Commissioner for Policy Coordination.*

[FR Doc. 98-29392 Filed 11-2-98; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 98D-0672]

#### Guidance on Criteria and Approaches for Postmarket Surveillance; Availability

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the